Voyager Therapeutics

VYGR

Market cap $210M

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.16 per share a year ago.

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective small molecules for people suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology. TDP-43 pathology is common in many neurodegenerative diseases, including over 90% of ALS cases1 and up to 45% of FTD cases2.

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results.

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT Company Participants Alfred Sandrock - President, CEO & Director Todd Carter - Chief Scientific Officer Nathan Jorgensen - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President I'm Sam Semenkow, one of the biotech analysts here at Citi, and it's my pleasure to be hosting Voyager Therapeutics. I'm joined by Al Sandrock, President and CEO; Nate Jorgensen, CFO; Todd Carter, CSO; and Trista Morrison, Chief of Communications.

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.18 per share a year ago.

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2025 financial and operating results.

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant -

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.